New therapeutic options for IBS: the role of the first in class mixed μ-opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline
New therapeutic options for IBS: the role of the first in class mixed μ-opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline
复制标题
DOI：
10.1080/17474124.2017.1298442
复制
发表时间：
2017-01-01
影响因子：
3.9
通讯作者：
Whorwell, Peter
中科院分区：
文献类型：
--
作者：
Corsetti, Maura;Whorwell, Peter
肠易激综合征（IBS）是一种常见的功能性胃肠道疾病，是医疗保健服务的主要成本。IBS-D患者约占IBS人群的三分之一，目前接受抗痉挛药、洛哌丁胺、胆汁酸螯合剂和抗抑郁药治疗。阿洛司琼和利福昔明也可在美国，雷莫司琼在日本，韩国和泰国和昂丹司琼作为一个标签外treatment.Areas covered：本文重点介绍eluxadoline，一种新的药理学药物，最近已被FDA和EMA批准用于治疗IBS-D患者。专家评论：eluxadoline在治疗排便习惯改变和疼痛方面的疗效和安全性，无论是在短期还是长期，都使该药物成为我们IBS-D治疗替代品中受欢迎的补充。其在任何IBS算法中的定位将取决于“真实的世界”中奥狄括约肌痉挛和轻度胰腺炎的小风险的患病率。
Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to healthcare services. IBS-D patients represent about one-third of the IBS population and are currently treated with antispasmodics, loperamide, bile acid sequestrants and antidepressants. Alosetron and rifaximin are also available in USA, ramosetron in Japan, Korea and Thailand and ondansetron as an off-label treatment.Areas covered: This article focuses on eluxadoline, a novel pharmacological agent that has recently been approved by both the FDA and EMA for treatment of patients with IBS-D.Expert commentary: The efficacy and safety of eluxadoline in treating bowel habit alterations and pain, both in the short and long-term, make the drug a welcome addition to our therapeutic alternatives in IBS-D. Its positioning in any IBS algorithm will depend on the 'real world' prevalence of the small risk of sphincter of Oddi spasm and mild pancreatitis.